Journal
DRUGS
Volume 66, Issue 12, Pages 1625-1656Publisher
ADIS INT LTD
DOI: 10.2165/00003495-200666120-00012
Keywords
orlistat; obesity; type 2 diabetes mellitus; metabolic syndrome; pharmacodynamics; pharmacokinetics; therapeutic use
Categories
Ask authors/readers for more resources
Orlistat (Xenical (R)) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data have shown that orlistat is also effective as a component of weight management strategies in obese adolescents. In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome. Orlistat is generally well tolerated. Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available